Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2026-06-02 Board/Management Inform…
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
6-K
Board/Management Information Classification · 90% confidence The document is a Form 6-K reporting the appointment and resignation of several directors and committee members, clearly detailing changes in the composition of the Board and its committees. There is no financial data or voting results—this is a Board/Management Information disclosure.
2026-06-02 English
6-K
Regulatory Filings
2026-05-14 English
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Chemomab Therapeutics Ltd., with the SEC. It includes a press release dated March 19, 2026, announcing year-end and fourth quarter 2025 financial results and a corporate update. The document itself is short (1883 characters) and primarily serves to furnish the press release as an exhibit. It does not contain the full financial statements or detailed financial analysis but references the press release for financial results. According to the rules, such a document is an announcement or furnishing of information rather than the full report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-03-19 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release dated November 20, 2025, titled 'Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update.' The document length is only 1795 characters, which is quite short and primarily serves to furnish the press release. The text states that the press release is attached as Exhibit 99.1 and is incorporated by reference into other registration statements. There is no substantive financial data or detailed financial statements within this document itself, only a summary and reference to the press release. According to the rules, short documents that announce or furnish reports without containing the full report themselves should be classified as Regulatory Filings (RNS). Therefore, this document is best classified as a Regulatory Filing (RNS).
2025-11-21 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Chemomab Therapeutics Ltd., which is a report of a foreign private issuer under the SEC Exchange Act. The content describes a ratio adjustment of American Depositary Shares (ADSs), effectively a reverse ADS split, with details on the new ratio, trading ticker, and depositary bank arrangements. There are no financial statements or detailed financial analysis present, and the document length is only 2362 characters, indicating it is a brief announcement rather than a full financial report. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about a capital structure change related to ADS ratio adjustment. According to the filing definitions, updates on capital structure changes such as share splits or ratio adjustments fall under Capital/Financing Update (CAP). Therefore, the appropriate classification is CAP with high confidence.
2025-08-22 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Chemomab Therapeutics Ltd., reporting unaudited condensed consolidated financial statements and Management's Discussion and Analysis for the three and six months ended June 30, 2025. It also includes a press release announcing second quarter 2025 financial results. Form 6-K is used for interim or quarterly reports by foreign private issuers. The document contains actual financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is under 5,000 characters but contains substantive financial data, so it is not a mere announcement. Therefore, the correct classification is Interim / Quarterly Report (IR).
2025-08-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.